GlaxoSmithKline PLC now has a chance to take over the US shingles vaccine market after the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) voted 8-7 to recommend Shingrix over Merck & Co. Inc.'s Zostavax.
The panel considered the appropriate use of Shingrix at its Oct. 25 meeting. Those who voted against recommending a preference...





